Protagonist Therapeutics, Inc. PTGX 深 滬
等待開盤 09-24 09:30:00 美东时间
138.70
-6.370
-4.39%
華盛通- 最 高145.28
- 今 開144.27
- 成交量 51.32万股
- 最 低 137.88
- 昨 收 145.07
- 總市值 89.75亿
- 52周最高 160.81
- 市盈率 靜 --
- 換手率 0.79%
- 52周最低 62.24
- 委 比 77.84%
- 總股本 6470.83万
- 歷史最高 160.81
- 量 比 0.57
- 振 幅 5.10%
- 歷史最低 4.47
- 每 手 1
- 風險率 24.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 美银上调微软目标价从500美元升至600美元；BlossomHill获小摩等多家大行首予买入评级
今日重点评级关注：BTIG：维持Kazia Therapeutics"买入"评级，目标价从34美元升至40美元；摩根大通：维持Annexon"超配"评级，目标价从10美元升至14美元
09-02 14:07
Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor Fitzgerald raised the price target for Sailpoint Inc (NASDAQ:SAIL) from $23 to $25. Cantor Fitzgerald a...
09-01 20:58
美股大行评级 | Affirm、GitLab获多家大行上调目标价；Attovia获大摩、花旗首予买入评级
今日重点评级关注：杰富瑞：维持拜玛林制药"买入"评级，目标价从104美元升至105美元；RBC Capital：维持Shift4 Payments"跑赢大市"评级，目标价从63美元升至67美元
09-01 08:37
Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug
On Friday, the U.S. Food and Drug Administration (FDA) approved Takeda Pharmaceutical Co. Ltd.‘s (NYSE:TAK) MIMRYLO (rusfertide) for polycythemia vera, a type of blood cancer. How MIMRYLO Combats Polycythemia Vera Polycythemia vera forces the human body to overproduce red blood cells. This harmful o...
09-01 00:38
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170
HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $167 to $170.
08-31 22:43
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $178
BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $178.
08-17 20:49
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma plc (NASDAQ:RPRX) on Wednesday entered into a $100 million funding agreement with Zealand Pharma in exchange for economic rights related to Zealand’s product, Rusfertide (PTG-300). This strategic move is expected to bolster Royalty Pharma’s portfolio and enhance its revenue streams. T...
08-14 01:07
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Goldman Sachs analyst Richard Law upgraded Protagonist Therapeutics Inc (NASDAQ:PTGX) from Neutra...
08-10 20:07
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
